期刊文献+

老年人9种性激素的化学发光免疫分析 被引量:6

Chemoluminescence immunoassay of nine reproductive hormones in the elderly
下载PDF
导出
摘要 目的探讨9种性激素在老年人中的变化。方法应用全自动微粒子化学发光免疫分析对180例老年人进行血清促黄体生成激素(LH)、促卵泡生成激素(FSH)、雌二醇(E2)、泌乳素(PRL)、孕酮(P)、17α-羟基孕酮(17α-OHP)、睾酮(T)、硫酸去氢表雄酮(DHEA-S)、雄烯二酮(A2)等9种性激素含量测定。结果绝经妇女的性激素水平较之育龄妇女有明显差别(P<0.001)。除LH和FSH呈高水平外,其他激素均明显低下,其中27例(59.4%)的E2接近零。成人男性组的E2、P、PRL和A2较女性为低,T、DHEA-S则高于女性;FSH、LH、17α-OHP近似女性女性卵泡期水平。老年男性组性激素水平与成年男性组比较略有差异。结论健康妇女绝经后性激素水平有显著的变化,老年男性与成年男性之间性激素水平略有差别。本研究提供了老年人9种性激素正常参考值。 Objective To explore the changes in nine sex hormones levels in the elderly. Methods Serum levels of nine sex hormones including luteotrophic hormone (LH), follicle-stimulating hormone (FSH), prolactin (PRL), estradiol (E2 ), progestone(P), testosterone (T), 17α-hydroxyprogesterone (17α-OHP), dehydroepiandrosterone sulfate (DHEA-SO4), andrestenedione (A2),were measured in 97 elderly by fully auto micreparticle chemiluminescence immune assay. Results Serum levels of sex hormones in menopausal women were significantly lowered (P 〈0.001 ) except LH and FSH, and E2 levels in 21 women were nearly undetectable. E2, P and PRL levels of the males were lowered than those of the females ,but T and DHEA-SO4 levels were higher and FSH,LH and 17α-OHP were similar to those of the women in follicular phase. There was slight difference in sex hormones between elderly male and adult male. Conclusions The sex hormone levels in healthy postmenopausal women have significant changes, while those in elderly male have slight difference, providing the normal reference values of nine sex hormones in the elderly.
出处 《中国老年学杂志》 CAS CSCD 北大核心 2006年第8期1030-1031,共2页 Chinese Journal of Gerontology
关键词 绝经期 性激素 正常值 Menopause Sex hormones Normal values
  • 相关文献

参考文献9

  • 1Morley JE.Testosterone & frailty[J].Clin Geriat Med,1997;13(4):685-95.
  • 2田军,石义刚,吴丽萍,陶天遵,陶树清,曲国藩.细胞因子、激素调节骨保护素和骨保护素配体基因表达及破骨细胞功能的研究进展[J].中国骨质疏松杂志,2004,10(1):122-124. 被引量:4
  • 3Mac Lennan AH.The trials and tribulations of long-term postmenopausal hormone therapy[J].Obstet Gynecol Surv,2004;59:65-7.
  • 4Chlebowski RT,Col N.Commentary:Menopausal hormone therapy after breast cancer[J].Lancet,2004;363:410-1.
  • 5Holmberg L,Anderson H.HABITS ﹙hormone replacement therapy after breast cancer-is it safe? a randomized comparison:trial stopped[J].Lancet,2004,363:453-5.
  • 6Siddiqui NA,Shetty KR,Duthie EH.Osteoporosis in older men:discovering,when & how to treat it[J].Geriatrics,1999;54:20-8.
  • 7Sun YP,Mao MW,Sun LH,et al.Treatment of osteoporosis in men using dehydroepiandrosterone[J].Chin Med J,2002;115:402-4.
  • 8Schulman C,Lunenfeld B.The ageing male[J].World J Urol,2002;20(1):4-10.
  • 9Hays J,Ockene JK,Brunner RL,et al.Effects of estrogen plus progestin on health-related qualify of life[M].N Engl J Med,2003;348:1939-54.

二级参考文献20

  • 1Tsuda E, Goto M, Mochizuki S, et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun, 1997,234:137-142.
  • 2Morony S, Capparelli C, Lee R, et al. A chimeric form of osteoprotegerin inhibits hypercaleemia and bone resorption induced by IL-1β, TNF-α ,PTH,PTHrP and 1,25(OH)2D3.J Bone Miner Res, 1999, 14: 1478-1485.
  • 3Kong YY, Felge U, Sarosi 1, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand.Nature, 1999,402:304-309.
  • 4Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis inhibitory factor and identical to TRANCE-RANK. Proc Natl Acad Sci USA, 1998,95:3597-3602.
  • 5Lacey DL,Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, 1998,93:165-176.
  • 6Anderson DM, Maraskovsky E, Billingsley WL, et al, A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature, 1997,390 : 175-179.
  • 7Kartsogiannis V,Zhou H, Horwood NJ,et al. Localization of RANK(receptor activator of nuclear kappa-B liand)mRNA and protein in skeletal and extraskeletal tissues. Bone, 1999,25:525-534.
  • 8Burgess TL. Qian YX, Kaufman S, et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol, 1999, 145:527-538.
  • 9Arai F, Miyamoto T, Ohneda O, et al. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fins and receptor activator of nuclear factor kappaB(RANK) receptors. J Exp Med, 1999,190:1741-1754.
  • 10Dougall WC,Glaccum M,Charrier K,et aI,RANK is essential for osteoclast and lymph node development. Genes Dev, 1999,13:2412-2424.

共引文献3

同被引文献51

引证文献6

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部